14th Annual Conference of the British HIV Association 23-25 April 2008, Belfast

A SINGLE CENTRE COHORT EXPERIENCE WITH DARUNAVIR/ RITONAVIR (DRV/R) (600 MG/100 MG) AND OPTIMISED BACKGROUND REGIMEN IN CLINICAL PRACTIVE

HIV Med 2008 Apr 23-25 (Suppl 1);14:14 (abstract no. P19)

C Scott, R Jogiya, A Teague, M Bower, B Gazzard and M Nelson
Chelsea and Westminster Healthcare NHS Foundation Trust, London, UK

BACKGROUND: Darunavir (DRV) is a novel non-peptidic protease inhibitor (PI) with activity against HIV-1 protease inhibitor resistant virus when boosted with low dose ritonavir.

METHODS: This study prospectively followed an established cohort of treatment experienced patients who received DRV/r 600/100 mg bd plus an optimised background regimen (OBR). OBR consisted of reverse transcriptase inhibitors ± PIs ± entry inhibitors ± integrase inhibitors. Baseline demographics, previous treatment experience and resistance tests were analysed. CD4 count and viral load where measured at baseline, 0, 12, 24, 36 and 48 week intervals.

RESULTS: 80 patients commenced DRV/r + OBR. All patients were heavily pre-treated with triple class experience. Reasons for DRV utilization were virological failure on current regimen: 62/80 and rationalisation of current treatment with VL < 50:18/80. Baseline median characterics (range): CD4 count = 225 cells/mm³ (10-951), VL = 10201 copies/mL (<50-500,000), number of drugs in OBR = 3 (0-5), previous ARV combinations = 11 (1-24) major PI mutations = 3 (0-7), minor PI mutations = 2 (0-7), DRV mutation score = 25 (0-63). Data were available for 42 patients up to 48 weeks of follow up. At week 48, median CD4 count increase and viral load reduction was 66 cells/mm³ and 2.31 log₁₀ copies/mL respectively. Only 3/42 patients discontinued treatment: drug intolerance (2) death from lymphoma (1). One patient was lost to follow up. 32/42 (76%) had VL < 50 copies at week 48.

CONCLUSIONS: DRV has shown impressive activity against protease resistant HIV in normal clinical practice and is well tolerated.

2008-04-23
P19

Copyright © 2008 - British HIV Association (BHIVA) Reproduction of this abstract (other than one copy for personal reference) must be cleared through the BHIVA Organising Secretariat 1 Mountview Court, 310 Friern Barnet Lane, London N20 0LD